XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Disaggregation of Revenue by Product
MIMEDX has two primary classes of products: (1) Advanced Wound Care, or Section 361, products, consisting of its tissue and cord sheet allograft products as well as certain particulate products regulated under Section 361, and (2) Section 351 products, consisting of the Company’s micronized and certain other particulate products. Advanced Wound Care is further disaggregated between the Company’s Tissue/Other and Cord products.
Information regarding the business units responsible for the sale of each of these classes of product can be found in Note 15, Segment Information.
Below is a summary of net sales by class of product (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Advanced Wound Care
Tissue/Other$61,131 $56,035 $174,256 $156,012 
Cord5,678 6,247 17,165 17,093 
Total Advanced Wound Care66,809 62,282 191,421 173,105 
Section 351796 489 1,815 17,187 
Other(1)
84 303 230 914 
Total$67,689 $63,074 $193,466 $191,206 
(1) “Other” represents revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups. This revenue is reflected as part of the Wound & Surgical segment.
Disaggregation of Revenue by Customer
MIMEDX has two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (“Direct Customers”), and (2) sales to distributors (“Distributors”).
Below is a summary of net sales by each customer type (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Direct Customers$65,898 $61,087 $188,231 $184,706 
Distributors1,791 1,987 5,235 6,500 
Net sales$67,689 $63,074 $193,466 $191,206 
The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three or nine months ended September 30, 2022 or 2021.